Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *


Period Start 2019-04-01 restructured
  Group Evotec (Group)
  Predecessor Evotec AG (FSE: EVT, TecDAX)
Products Industry drug discovery technology
  Industry 2 drug discovery services
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Rouxel, Laetitia (Evotec 202304– CFO before Wavin + Coty + Danone + JnJ + Pfizer)
Region Region Hamburg
  Country Germany
  Street 7 Essener Bogen
  City 22419 Hamburg
    Address record changed: 2022-09-17
Basic data Employees F: 1,001 to 5,000 (2022-12-31)
  Currency EUR
  Annual sales 751,448,000 (revenues, consolidated (2022) 2022-12-31)
  Profit -175,655,000 (2022-12-31)
  Cash 415,155,000 (2022-12-31)
    * Document for »About Section«: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg.
Record changed: 2023-10-05


Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Stier Group MIXiii Lifescience Healthtech Conference 650x300px

» top